HB
REGN icon

Homrich & Berg’s Regeneron Pharmaceuticals REGN Stock Holding History

Homrich & Berg’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-530
Closed -$270K – 275
2015
Q2 		$270K Sell
530
-19
-3% -$9.27K 0.03% 215
2015
Q1 		$248K Hold
549
– – 0.02% 211
2014
Q4 		$225K Buy
+549
New +$216K 0.02% 210

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Homrich & Berg's REGN Position: Q3 2015 in Review

Homrich & Berg sold out of Regeneron Pharmaceuticals (REGN) in Q3 2015, closing a stake of 530 shares — an estimated $270K sold.

Homrich & Berg first reported a position in REGN in Q4 2014 and held it in 3 quarters. The position peaked at $270K in Q2 2015. 563 funds tracked by Wall St. Rank hold REGN as of Q3 2015.

  • Homrich & Berg reported no remaining Regeneron Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Homrich & Berg sold 530 Regeneron Pharmaceuticals shares in Q3 2015, an estimated $270K.
  • Homrich & Berg first reported a position in Regeneron Pharmaceuticals in Q4 2014 and held it in 3 quarters.
  • Homrich & Berg's Regeneron Pharmaceuticals position peaked at $270K in Q2 2015.
  • 563 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2015.

Based on Homrich & Berg's 13F filing for Q3 2015, filed 10 Nov 2015.